The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: A meta-analysis of randomized controlled trials

Journal of Korean Medical Science

Volumn 29, Issue 6, 2014, Pages 811-817

  Pak, Kyoungjune ^a,b   Cheon, Gi Jeong ^a   Kang, Keon Wook ^a   Kim, Seong Jang ^b   Kim, In Joo ^b   Edmund Kim, E ^c,d   Lee, Dong Soo ^a,c   Chung, June Key ^a  

^a Seoul National University Hospital   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Thyroid neoplasms; Thyrotropin alfa

Indexed keywords

RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT PROTEIN; THYROGLOBULIN; THYROTROPIN;

BIOSYNTHESIS; CATHETER ABLATION; CLINICAL TRIAL (TOPIC); ECHOGRAPHY; FACTUAL DATABASE; GENETICS; HUMAN; META ANALYSIS; METABOLISM; RISK; THYROID NEOPLASMS; TREATMENT OUTCOME; WHOLE BODY IMAGING;

CATHETER ABLATION; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HUMANS; IODINE RADIOISOTOPES; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; RISK; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 84923363467     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.6.811     Document Type: Article

References (34)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-41.
2. Lang BH, Law TT. The role of 18F-fluorodeoxyglucose positron emission tomography in thyroid neoplasms. Oncologist 2011; 16: 458-66.
3. Robbins RJ, Schlumberger MJ. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med 2005; 46: 28S-37S.
4. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-214.
5. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006; 91: 926-32.
6. Ma C, Xie J, Liu W, Wang G, Zuo S, Wang X, Wu F. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. Cochrane Database Syst Rev 2010; (11): CD008302.
7. Chianelli M, Todino V, Graziano FM, Panunzi C, Pace D, Guglielmi R, Signore A, Papini E. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol 2009; 160: 431-6.
8. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savo-vic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
10. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
11. Taïeb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, De Micco C, Vaillant J, Thomas S, Conte-Devolx B, et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf) 2009; 71: 115-23.
12. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 2010; 20: 173-9.
13. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Bardet S, Leenhardt L, Bastie D, Schvartz C, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012; 366: 1663-73.
14. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012; 366: 1674-85.
15. Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid 1997; 7: 163-76.
16. Chung JK, Youn HW, Kang JH, Lee HY, Kang KW. Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma. Nucl Med Mol Imaging 2010; 44: 4-14.
17. Hugo J, Robenshtok E, Grewal R, Larson S, Tuttle RM. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid 2012; 22: 1007-15.
18. Coliez R, Tubiana M, Dutreix J, Guelfi J. Results of examination of 85 cases of cancer of the thyroid with radioactive iodine. J Radiol Electrol Arch Electr Medicale 1951; 32: 881-95.
19. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Turco A, Mariani G. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nucl Med Commun 2006; 27: 627-32.
20. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84: 3877-85.
21. Rosário PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 2008; 49: 1776-82.
22. Taïeb D, Sebag F, Farman-Ara B, Portal T, Baumstarck-Barrau K, Fortanier C, Bourrelly M, Mancini J, De Micco C, Auquier P, et al. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. J Clin Endocrinol Metab 2010; 95: 3283-90.
23. Frigo A, Dardano A, Danese E, Davì MV, Moghetti P, Colato C, Francia G, Bernardi F, Traino C, Monzani F, et al. Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal. J Clin Endocrinol Metab 2009; 94: 3472-6.
24. Vallejo Casas JA, Mena Bares LM, Gálvez MA, Marlowe RJ, Latre Romero JM, Martínez-Paredes M. Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of thyroid-stimulating hormone stimulation methods. Nucl Med Commun 2011; 32: 840-6.
25. Borget I, Corone C, Nocaudie M, Allyn M, Iacobelli S, Schlumberger M, De Pouvourville G. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol 2007; 156: 531-8.
26. Mernagh P, Campbell S, Dietlein M, Luster M, Mazzaferri E, Weston AR. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 2006; 155: 405-14.
27. Dohán O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS, Carrasco N. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 2003; 24: 48-77.
28. Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer 2006; 13: 797-826.
29. Andros G, Wollman SH. Autoradiographic localization of radioiodide in the thyroid gland of the mouse. Am J Physiol 1967; 213: 198-208.
30. Kogai T, Endo T, Saito T, Miyazaki A, Kawaguchi A, Onaya T. Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology 1997; 138: 2227-32.
31. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997; 7: 265-71.
32. 131I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. J Clin Endocrinol Metab 2013; 98: 2693-700.
33. Ahn BC, Lee WK, Jeong SY, Lee SW, Lee J. Estimation of true serum thyroglobulin concentration using simultaneous measurement of serum antithyroglobulin antibody. Int J Endocrinol 2013; 2013: 210639.
34. Yoo ID, Kim SH, Seo YY, Oh JK, O JH, Chung SK. The success rate of initial 131I ablation in differentiated thyroid cancer: comparison between less strict and very strict low iodine diets. Nucl Med Mol Imaging 2012;46:34-40.